- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Regeneron Pharmaceuticals Inc (REGN)
Regeneron Pharmaceuticals Inc stock price live, this page displays NASDAQ REGN stock exchange data. View the REGN premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Regeneron Pharmaceuticals Inc real time stock price chart below.
What Is the Regeneron Pharmaceuticals Inc Stock Price Today?
The Regeneron Pharmaceuticals Inc stock price today is 785.51.
What Is the Stock Symbol for Regeneron Pharmaceuticals Inc?
The stock symbol for Regeneron Pharmaceuticals Inc is "REGN."
What Stock Exchange Does Regeneron Pharmaceuticals Inc Trade On?
Regeneron Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Regeneron Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Regeneron Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the REGN quote. (ISIN: US75886F1075)
What Is the Regeneron Pharmaceuticals Inc Stock Price Today?
The Regeneron Pharmaceuticals Inc stock price today is 785.51.
What Is the Stock Symbol for Regeneron Pharmaceuticals Inc?
The stock symbol for Regeneron Pharmaceuticals Inc is "REGN."
What Stock Exchange Does Regeneron Pharmaceuticals Inc Trade On?
Regeneron Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Regeneron Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Regeneron Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the REGN quote. (ISIN: US75886F1075)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
764.78
786.99
52 wk Range
476.49
821.11
REGN is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
764.78786.99
52 wk Range
476.49821.11
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(0.48%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(0.48%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
REGN Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Price Target
859.58
Upside
+9.43%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
5 analysts have revised their earnings downwards for the upcoming period
- Regeneron Phar. receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- Regeneron Phar. receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Regeneron Phar. receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Regeneron Phar. receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Regeneron Pharmaceuticals Inc Company Profile
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoid arthritis. In addition, the company provides Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; Evkeeza for HoFH; Ordspono to treat Follicular lymphoma and Diffuse large B-cell lymphoma; Lynozyfic for relapsed multiple myeloma; and Veopoz for CD55-deficient protein-losing enteropathy. It has license and collaboration agreement with Bayer for the development and commercialization of EYLEA 8 mg and EYLEA; Alnylam Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for diseases by addressing therapeutic disease targets expressed in the eye and central nervous system; Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for in vivo therapeutic development for therapies focused on neurological and muscular diseases; Hansoh Pharmaceuticals Group Company Limited to acquire development and commercial rights for HS-20094, a dual GLP-1/GIP receptor; and Tessera Therapeutics, Inc. develops and commercializes TSRA-196, an investigational gene editing therapy for Alpha-1 antitrypsin deficiency. The company was incorporated in 1988 and is based in Tarrytown, New York.
Regeneron Pharmaceuticals Inc SWOT Analysis
Eylea's Challenges | Explore Regeneron's strategy to maintain Eylea's market position amid biosimilar competition and regulatory hurdles, impacting its $4 billion franchise |
Dupixent's Ascent | Discover how Dupixent's expansion into new indications could drive Regeneron's growth, with analysts projecting an 8% CAGR from 2025 to 2030 |
Pipeline Potential | Delve into Regeneron's promising oncology and immunology pipeline, including fianlimab for melanoma and itepekimab for COPD |
Financial Outlook | Analysts maintain a positive outlook with EPS estimates around $34.50 for 2025. Price targets range from $695 to $1,215, averaging around $990 |
Regeneron Pharmaceuticals Inc Earnings Call Summary for Q3/2025
- Q3 2025 EPS of $11.83 beat $9.64 forecast; revenue reached $3.8B, slightly above expectations; stock rose 8.75% to $608 pre-market
- Strong sales growth in Dupixent and Libtayo; company plans $7B+ investment in manufacturing facilities in NY and NC
- Mid-teens percentage increase in R&D expenses expected for 2026; advancing pivotal programs in myeloma, lymphoma, and obesity
- Executives optimistic about drug pricing negotiations with U.S. government; emphasize potential of ophthalmology programs
- Risks include regulatory challenges, drug pricing pressures, market competition, and economic uncertainties affecting healthcare spending
Last Updated: 10/28/2025, 10:30 PM
Read Full TranscriptCompare REGN to Peers and Sector
Metrics to compare | REGN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipREGNPeersSector | |
|---|---|---|---|---|
P/E Ratio | 17.9x | 20.7x | −0.5x | |
PEG Ratio | 2.18 | 0.45 | 0.00 | |
Price/Book | 2.6x | 3.2x | 2.6x | |
Price / LTM Sales | 5.6x | 3.9x | 3.3x | |
Upside (Analyst Target) | 10.5% | 21.7% | 45.7% | |
Fair Value Upside | Unlock | 27.7% | 6.5% | Unlock |
Analyst Ratings
19 Buy
8 Hold
0 Sell
Ratings:
27 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 859.58
(+9.43% Upside)
Earnings
Latest Release
Jan 30, 2026
EPS / Forecast
11.44 / 10.52
Revenue / Forecast
3.88B / 3.77B
People Also Watch
FAQ
What Is the Regeneron Pharma (REGN) Stock Price Today?
The Regeneron Pharma stock price today is 785.51
What Stock Exchange Does Regeneron Pharma Trade On?
Regeneron Pharma is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Regeneron Pharma?
The stock symbol for Regeneron Pharma is "REGN."
Does Regeneron Pharma Pay Dividends? What’s The Current Dividend Yield?
The Regeneron Pharma dividend yield is 0.48%.
What Is the Regeneron Pharma Market Cap?
As of today, Regeneron Pharma market cap is 80.61B.
What Is Regeneron Pharma's Earnings Per Share (TTM)?
The Regeneron Pharma EPS (TTM) is 43.07.
When Is the Next Regeneron Pharma Earnings Date?
Regeneron Pharma will release its next earnings report on Apr 29, 2026.
From a Technical Analysis Perspective, Is REGN a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Regeneron Pharma Stock Split?
Regeneron Pharma has split 0 times.
How Many Employees Does Regeneron Pharma Have?
Regeneron Pharma has 15410 employees.
What is the current trading status of Regeneron Pharma (REGN)?
As of Feb 07, 2026, Regeneron Pharma (REGN) is trading at a price of 785.51, with a previous close of 766.63. The stock has fluctuated within a day range of 764.78 to 786.99, while its 52-week range spans from 476.49 to 821.11.
What Is Regeneron Pharma (REGN) Price Target According to Analysts?
The average 12-month price target for Regeneron Pharma is USD859.58, with a high estimate of USD1057 and a low estimate of USD730. 19 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +9.43% Upside potential.
What Is the REGN Premarket Price?
REGN's last pre-market stock price is 770.80. The pre-market share volume is 850.00, and the stock has decreased by 4.17, or 0.54%.
What Is the REGN After Hours Price?
REGN's last after hours stock price is 783.66, the stock has decreased by -1.85, or -0.24%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.